|
1,930
|
| 14975 |
Cxcr4
|
|
interacts (colocalizes) with
|
Cxcl12
|
to retain HSCs in BM niches
|
|
|
21211783
|
|
2,628
|
| 25008 |
Angpt1
|
|
decreases_expression of
|
Cxcr4
|
in LT-HSC (Tie2+SP,KSL)
|
in vitro
|
|
15260986
|
|
2,761
|
| 25584 |
CAR cell
|
|
increases_expression of
|
Cxcl12
|
|
in vivo
|
|
20850355
|
|
2,766
|
| 25616 |
Cxcl12
|
|
interacts (colocalizes) with
|
Cxcr4
|
|
|
| 25632 |
Cxcr4
|
|
increases_expression of
|
Vegfa
|
in HSC (CD34-KSL)
|
in vivo
|
| 25633 |
Cxcr4
|
|
increases_expression of
|
Junb
|
in HSC (CD34-KSL)
|
in vivo
|
| 25634 |
Cxcr4
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
in vivo
|
| 25636 |
Cxcl12
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
in vivo
|
| 25640 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Cxcr4
|
compared to CD34+KSL progenitor cells
|
in vivo
|
| 25648 |
CAR cell
|
|
increases_quantity of
|
Cxcl12
|
|
in vivo
|
| 26819 |
Cxcr4
|
|
increases_expression of
|
Tek
|
in HSC (CD34-KSL)
|
in vivo
|
| 30460 |
CXCL12/CXCR4 signaling
|
|
increases_activity of
|
repopulation >16 weeks
|
|
in vivo
|
| 30461 |
CXCL12/CXCR4 signaling
|
|
increases_activity of
|
quiescence
|
|
|
|
17174120
|
|
2,824
|
| 26083 |
osteoblast (osteopontin+)
|
|
increases_quantity of
|
Cxcl12
|
in the transgenic stroma; via PPR induction
|
|
|
14574413
|
|
2,830
|
| 26148 |
irradiation
|
|
increases_expression of
|
Cxcl12
|
in trabecular bone area
|
|
|
19052548
|
|
2,856
|
| 26374 |
primary MSC-enriched cell (Alcam-Sca1+)
|
|
increases_expression of
|
Cxcl12
|
|
|
|
20472830
|
|
2,878
|
| 26541 |
osteoblast
|
|
increases_expression of
|
Cxcl12
|
in Wif1-overexpressing osteoblasts. Expression is not influenced by 5-FU treatment
|
in vivo
|
| 26543 |
Wif1
|
|
increases_expression of
|
Cxcl12
|
in Wif1-overexpressing osteoblasts. Expression is not influenced by 5-FU treatment
|
in vivo
|
|
21652676
|
|
2,937
|
| 26833 |
mir-886-3p
|
|
decreases_expression of
|
Cxcl12
|
in BM stromal cells; by directly binding to the 3' UTR of Cxcl12 mRNA
|
in vitro
|
|
21179442
|
|
3,138
|
| 28901 |
Cxcl12
|
|
increases_quantity of
|
Mmp9
|
in stromal and hematopoietic cells
|
in vivo
|
| 30544 |
5-FU
|
|
increases_quantity of
|
Cxcl12
|
in plasma
|
in vivo
|
| 31588 |
Mmp9
|
|
increases_processing of
|
Kitl
|
by cleaving off a N-terminal peptide
|
in vivo
|
|
12062105
|
|
3,182
|
| 29207 |
MSC (Nes+)
|
|
increases_expression of
|
Cxcl12
|
in contrast to osteoblasts or osteoclasts
|
|
|
20703299
|
|
3,262
|
| 30474 |
Robo4
|
|
decreases_expression of
|
Cxcr4
|
in LT-HSC (CD34-CD135-KSL), but not in MPPs; Loss of Robo4 is compensated by upregulating Cxcr4 and Cxcl12.
|
in vivo
|
| 30479 |
Robo4
|
|
decreases_expression of
|
Cxcl12
|
in BM stromal cells; Loss of Robo4 is compensated by upregulating Cxcr4 and Cxcl12.
|
in vivo
|
| 30480 |
Robo4
|
|
increases_activity of
|
homing
|
to the BM; in cooperation with Cxcr4
|
in vivo
|
|
21211783
|
|
3,322
|
| 30532 |
CXCL12/CXCR4 signaling
|
|
increases_activity of
|
quiescence
|
|
in vivo
|
| 30539 |
CXCL12/CXCR4 signaling
|
|
increases_activity of
|
homing
|
of HSC (CD135-KSL) into the BM, but is less critical for retention in the BM
|
vivo
|
| 30542 |
CXCL12/CXCR4 signaling
|
|
increases_expression of
|
Cdkn1c
|
in HSC (CD135-CD48-KSL)
|
in vivo
|
| 30674 |
Cxcl12
|
|
increases_activity of
|
non-cell autonomous activity
|
|
|
| 32049 |
CXCL12/CXCR4 signaling
|
|
decreases_expression of
|
Ccnd1
|
in HSC (CD135-CD48-KSL)
|
|
|
18378795
|
|
3,337
|
| 30646 |
Hyaluronate
|
|
increases_quantity of
|
Cxcl12
|
|
in vitro
|
|
22654110
|
|
3,373
|
| 31400 |
Csf3
|
|
decreases_quantity of
|
Cxcl12
|
in the bone. The amount of Cxcl12 was not affected in Cgt knockout mice
|
in vivo
|
|
16439213
|
|
3,378
|
| 31439 |
HSC (CD150+CD48-CD41-KSL)
|
|
increases_expression of
|
Cxcr4
|
|
in vivo
|
| 31441 |
Anxa2
|
|
interacts (colocalizes) with
|
Cxcl12
|
This interaction facilitates presentation of Cxcl12 to HSCs
|
in vitro
|
| 31445 |
Anxa2
|
|
affects_activity of
|
Cxcl12
|
|
in vitro
|
|
21108988
|
|
3,583
|
| 33571 |
perivascular cell (Lepr+)
|
|
increases_expression of
|
Cxcl12
|
|
|
|
22281595
|
|
3,680
|
| 35304 |
non-myelinated Schwann cell (GFAP+)
|
|
increases_expression of
|
Cxcl12
|
|
|
|
22118468
|
|
3,684
|
| 35342 |
Ca2+
|
|
increases_transport of
|
Cxcl12
|
|
in vitro
|
|
21441933
|
|
3,687
|
| 35470 |
Prostaglandin E2
|
|
increases_expression of
|
Cxcr4
|
in HSC (KSL)
|
|
| 35479 |
Prostaglandin E2
|
|
increases_expression of
|
Cxcl12
|
in MSC (Nes+) cells known to co-localize with HSC (CD150+CD48-Lin-)
|
|
|
22983360
|
|
3,689
|
| 37315 |
macrophage (CD169+)
|
|
increases_quantity of
|
Cxcl12
|
in the BM stroma
|
|
|
21282381
|
|
3,835
|
| 38505 |
Pim1
|
|
affects_activity of
|
Cxcr4
|
|
in vitro
|
|
23360755
|
|
3,881
|
| 39151 |
Nfe2l2
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
in vivo
|
|
23434824
|
|
3,895
|
| 39456 |
CAR cell
|
|
increases_expression of
|
Cxcl12
|
in comparison to osteoblasts and endothelial cells
|
|
| 39462 |
CAR cell
|
|
increases_quantity of
|
Cxcl12
|
in comparison to osteoblasts and endothelial cells
|
|
| 39475 |
Cxcl12
|
|
increases_activity of
|
repopulation >16 weeks
|
of CD150+CD48-CD41-KSL cells; if Cxcl12 is expressed in mesenchymal progenitors (Nes-Prx1+)
|
in vivo
|
| 39480 |
Cxcl12
|
|
increases_activity of
|
quiescence
|
if Cxcl12 is expressed in mesenchymal progenitors (Nes-Prx1+)
|
in vivo
|
|
23434756
|
HSC